Deucravacitinib Market

The Deucravacitinib market is on a sharp growth trajectory, owing to its recent approval and promising clinical potential as a first-in-class oral, selective TYK2 (tyrosine kinase 2) inhibitor. Developed primarily for the treatment of moderate to severe plaque psoriasis, Deucravacitinib represents a breakthrough in immunomodulatory therapy by targeting the JAK-STAT pathway more selectively, offering fewer off-target effects compared to traditional JAK inhibitors.

Approved by the U.S. FDA in 2022, Deucravacitinib (brand name: Sotyktu) has quickly gained attention from dermatologists and immunologists for its favorable efficacy-safety profile. The market was valued at USD 215 million in 2024 and is projected to exceed USD 640 million by 2035, expanding at a CAGR of 11.4%. This rise is strongly supported by an increasing global prevalence of autoimmune diseases, such as psoriasis and lupus, and ongoing clinical trials in other indications like psoriatic arthritis and systemic lupus erythematosus (SLE).

North America: Currently the largest regional market, led by the U.S., where Deucravacitinib has already received FDA approval and is being prescribed widely. The strong presence of BMS and advanced dermatology care centers contributes to early adoption.

Asia-Pacific: Expected to witness the fastest growth rate, especially in Japan, South Korea, and Australia, driven by increasing diagnosis rates, rising healthcare spending, and strategic expansion by BMS and its partners.

Latin America & Middle East: Emerging markets with increasing availability through regulatory approvals. Brazil and Saudi Arabia are key countries experiencing growing demand for next-generation immunomodulatory drugs.